HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy.

Abstract
Exposure to 1,3-dinitrobenzene (DNB) is associated with neuropathologic changes in specific brainstem nuclei, mediated by oxidative stress and mitochondrial dysfunction. The expression of Bcl-2-family proteins as a function of sensitivity to 1, 3-dinitrobenzene (DNB)-induced mitochondrial permeability transition (MPT) was examined in C6 glioma and SY5Y neuroblastoma cells. Neuroblastoma cells were 10-fold more sensitive than glioma cells to DNB-induced decreases in mitochondrial reducing potential, measured by reduction of the tetrazolium compound, 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT). The IC(50) values for DNB-related inhibition of MTT reduction were 107+/-25 microM in SY5Y cells and 1047+/-101 microM in C6 cells. Levels of reactive oxygen species (ROS) were increased in both SY5Y and C6 cells following DNB exposure by 4.6- and 6.0-fold above control, respectively. DNB caused abrupt depolarization of mitochondria in both neuroblastoma and glioma cells that was inhibited by trifluoperazine. The first order rate constants for mitochondrial depolarization were: C6, k=0.31+/-0.02 min(-1); SY5Y, k=0.14+/-0.01 min(-1). Onset of MPT occurred at 10-fold lower concentration of DNB in SY5Y cells than in C6 cells. The antioxidants, deferoxamine and alpha-tocopherol, effectively prevented DNB-induced MPT in C6 and SY5Y cells, suggesting involvement of ROS in the initiation of MPT. Exposure to DNB resulted in decreased cellular ATP content in SY5Y cells and efflux of mitochondrial calcium in both SY5Y and C6 cells, concurrent with onset of MPT. The expression of Bcl-2, Bcl-X(L), and Bax was evaluated in both cell types by Western blot analysis. C6 glioma cells strongly expressed Bcl-X(L) and only weakly expressed Bcl-2 and Bax, whereas SY5Y neuroblastoma cells expressed lower levels of Bcl-X(L) and higher levels of both Bcl-2 and Bax. Collectively, these results suggest that higher constitutive expression of Bcl-X(L), rather than Bcl-2, correlates with resistance to DNB-induced MPT in SY5Y and C6 cells and that differential regulation of the permeability transition pore may underlie the cell-specific neurotoxicity of DNB.
AuthorsR B Tjalkens, M M Ewing, M A Philbert
JournalBrain research (Brain Res) Vol. 874 Issue 2 Pg. 165-77 (Aug 25 2000) ISSN: 0006-8993 [Print] Netherlands
PMID10960601 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antioxidants
  • BAX protein, human
  • BCL2L1 protein, human
  • Dinitrobenzenes
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Reactive Oxygen Species
  • Tetrazolium Salts
  • Thiazoles
  • bcl-2-Associated X Protein
  • bcl-X Protein
  • Vitamin E
  • Trifluoperazine
  • Adenosine Triphosphate
  • 3-dinitrobenzene
  • thiazolyl blue
  • Deferoxamine
  • Calcium
Topics
  • Adenosine Triphosphate (metabolism)
  • Antioxidants (pharmacology)
  • Brain Diseases (chemically induced, pathology, physiopathology)
  • Calcium (metabolism)
  • Deferoxamine (pharmacology)
  • Dinitrobenzenes (pharmacology)
  • Electrophysiology
  • Glioma (metabolism, pathology, physiopathology)
  • Humans
  • Mitochondria (drug effects, metabolism, physiology)
  • Neuroblastoma (metabolism, pathology, physiopathology)
  • Oxidation-Reduction (drug effects)
  • Permeability
  • Proto-Oncogene Proteins (metabolism)
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Reactive Oxygen Species (metabolism)
  • Tetrazolium Salts (metabolism)
  • Thiazoles (metabolism)
  • Trifluoperazine (pharmacology)
  • Tumor Cells, Cultured
  • Vitamin E (pharmacology)
  • bcl-2-Associated X Protein
  • bcl-X Protein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: